Inmune Bio Inc Stock Price, News & Analysis

INmune Bio (NASDAQ: INMB) reported new Phase 2 neuroimaging analyses from the MINDFuL trial of XPro1595 in early Alzheimer’s disease patients with elevated neuroinflammation (ADi). Presented at CTAD Dec 1-4, 2025, the PerpPD+ grey-matter MRI analysis showed a trend toward slowed progression of cortical disarray in XPro1595-treated, dose-compliant ADi participants at 24 weeks.

The company says these imaging signals align with directional improvements in biological, cognitive, and neuropsychiatric endpoints and that additional MRI analyses are expected in 2026.

INmune Bio (NASDAQ: INMB) will present two scientific posters at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) in San Diego on Dec 1–4, 2025. The company will present Phase 2 MINDFuL results for XPro1595 (a selective soluble TNF neutralizer) during a session running from 3:30 PM Dec 1 to 5:30 PM Dec 2 PT at location P057 with presenting author Kim A. Staats, PhD. A second presentation, led by Sarah Barnum, PhD of Cognition Metrics, will report validation work on the Early Mild Alzheimer’s Cognitive Composite (EMACC) and its associations with blood biomarkers on Dec 4, 2025 at location P316.

INmune Bio (NASDAQ: INMB) reported Q3 2025 results and operational milestones on October 30, 2025. The company posted a net loss of $6.5M vs $12.1M in Q3 2024 and held $27.7M cash as of September 30, 2025, with ~26.6M shares outstanding as of October 30, 2025.

Clinical progress: completed two pilot-scale CORDStrom manufacturing runs with an MAA planned mid-2026 and anticipated subsequent BLA; XPro1595 (DN-TNF) Phase 2 MINDFuL data show clinical benefits in an amyloid-positive, high-inflammation subgroup and an excellent safety profile; INKmune CARE-PC met its primary endpoint and two secondary endpoints with final data pending.

INmune Bio (NASDAQ: INMB) will report third-quarter 2025 financial results and provide a corporate update on Thursday, October 30, 2025. Management will host a conference call and live audio webcast at 4:30 PM Eastern Time to discuss results for the quarter ended September 30, 2025.

Dial-in details: domestic 1-800-225-9448, international 1-203-518-9708, Conference ID: INMUNE. The live webcast is available at the company webcast link. A transcript will be posted ~24 hours after the call. A replay is available through November 13, 2025 by dialing 1-844-512-2921 or 1-412-317-6671 (international) and entering PIN 11159914.

INmune Bio (NASDAQ: INMB) announced that CEO David Moss will participate in a Dermatologic Rare Disease Panel at the Maxim Growth Summit on October 22, 2025 in New York City.

The panel is moderated by Jason McCarthy, Ph.D. and Mr. Moss will discuss INmune Bio’s CORDStrom™ advanced cell platform for treating Recessive Dystrophic Epidermolysis Bullosa (RDEB). Mr. Moss will be available for one-on-one meetings during the conference. Event dates: Oct 22–23, 2025; panel time: Oct 22, 8:30am ET. Registration information is provided on the event page.

INmune Bio (NASDAQ: INMB) has submitted results from its Phase 2 MINDFuL trial of XPro™ in Alzheimer's disease to npj Dementia journal. While the trial did not meet its primary endpoint in the overall population, it showed promising results in a specific subgroup of patients with both amyloid pathology and high inflammatory burden (ADi population).

Key findings in the ADi population demonstrated positive trends across cognitive, neuropsychiatric, and biological endpoints. Notably, XPro™ showed a complete absence of amyloid-related imaging abnormalities (ARIA), a common side effect in other Alzheimer's treatments, even in high-risk patients including APOE4 carriers. The company expects FDA regulatory feedback in Q1 2026.

INmune Bio (NASDAQ: INMB) has successfully completed its first commercial pilot-scale manufacturing run of CORDStrom™, a cell therapy treatment for Recessive Dystrophic Epidermolysis Bullosa (RDEB), at the Cell and Gene Therapy Catapult facility in the UK.

The milestone keeps the company on track for filing a Marketing Authorization Application (MAA) in the UK during H1 2026, followed by a Biologics License Application (BLA) in the US. CORDStrom™, which showed promising results in Phase 2 trials, is an off-the-shelf, allogeneic therapy derived from umbilical cord tissue mesenchymal stromal cells.

The successful manufacturing run demonstrates the scalability and consistency of CORDStrom™ production using a proprietary GMP-compliant process, marking a crucial step toward commercialization for treating RDEB patients.

INmune Bio (NASDAQ: INMB) reported Q2 2025 financial results and announced significant management changes. The company's MINDFuL phase 2 trial for Alzheimer's missed its primary cognitive endpoints in the overall population but showed positive trends in a pre-defined subset of patients with inflammation biomarkers. The company reported a net loss of $24.5 million for Q2 2025, compared to $9.7 million in Q2 2024.

Key developments include CEO RJ Tesi's retirement, with David Moss appointed as President & CEO, Cory Ellspermann as Interim CFO, and Kelly Ganjei as Board Chairman. The company successfully closed a $19 million registered direct offering and ended the quarter with $33.4 million in cash. INmune Bio plans to file MAA and BLA applications for CORDStrom™ in RDEB by mid-2026.

INmune Bio (NASDAQ: INMB) announced the successful completion of its Phase I/II CaRe PC trial for INKmune™ in metastatic castration-resistant prostate cancer (mCRPC). The trial met both primary and secondary endpoints, with the treatment demonstrating excellent safety across all three dose levels.

Key findings include successful NK cell activation in over 50% of patients with advanced disease, with some patients showing tumor size reduction or complete disappearance. Following these positive results, the company plans to advance to a randomized Phase 2b trial focusing on patients with less severe disease to better evaluate the drug's clinical benefits.